Other Events ·
At its annual meeting on June 18, 2026, Precigen, Inc. stockholders approved an amendment to the 2023 Omnibus…
PGENPrecigen, Inc.
At its annual meeting on June 18, 2026, Precigen, Inc. stockholders approved an amendment to the 2023 Omnibus Incentive Plan to increase the number of common shares available for issuance by 7 million. Additionally, shareholders elected nine directors for one-year terms, ratified Deloitte & Touche LLP as the independent registered public accounting firm for the 2026 fiscal year, and approved a non-binding advisory resolution regarding executive compensation. Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies.